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Abstract: A cyclic peptide containing one cysteine and five alternating tryptophan and arginine
amino acids [(WR)5 C] was synthesized using Fmoc/tBu solid-phase methodology. The ability of the
synthesized cyclic peptide to produce gadolinium nanoparticles through an in situ one-pot mixing of
an aqueous solution of GdCl3 with [(WR)5 C] peptide solution was evaluated. Transmission electron
microscopy showed the formed peptide-Gd nanoparticles in star-shape morphology with a size
of ~250 nm. Flow cytometry investigation showed that the cellular uptake of a cell-impermeable
fluorescence-labeled phosphopeptide (F0 -GpYEEI, where F0 = fluorescein) was approximately six
times higher in the presence of [(WR)5 C]-Gd nanoparticles than those of F0 -GpYEEI alone in human
leukemia adenocarcinoma (CCRF-CEM) cells after 2 h incubation. The antiproliferative activities
of cisplatin and carboplatin (5 µM) were increased in the presence of [(WR)5 C]-GdNPs (50 µM) by
41% and 18%, respectively, after 72-h incubation in CCRF-CEM cells. The intracellular release of
epirubicin, an anticancer drug, from the complex showed that 15% and 60% of the drug was released
intracellularly within 12 and 48 h, respectively. This report provides insight about using a non-toxic
MRI agent, gadolinium nanoparticles, for the delivery of various types of molecular cargos.
Keywords: drug delivery systems; cyclic peptides; gadolinium nanoparticles; intracellular
transportation; nanocarriers

1. Introduction
Metal-containing materials have been used extensively in designing various biomedical projects
such as imaging cargos, detection markers and therapeutics [1,2]. Optimized functionality of
metal-containing materials could be obtained by utilizing various elements such as size, active
surface, morphology and stability properties. Therefore, researchers have made their best effort to tailor
the orientation of functional groups in drug delivery systems to achieve their optimized function [3,4].
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A member of the lanthanide family, gadolinium (Gd) has exhibited extensive potency for clinical
applications due to its unparalleled chemical properties [5]. Gadolinium offers a paramagnetic property
due to the presence of seven unpaired electrons in the 4f shell, which makes it a potential agent for
magnetic resonance imaging (MRI) [6]. It enhances MR images by reducing T1 relaxation constant
of the tissues in which accumulated. Gd has been shown to be able to chelate to various types of
ligands and form stable complexes. Gd-DTPA (Magnevist) and Gd-DOTA (Dotarem) are examples of
commercially available products that are being used as T1 contrast agents. Although Gd containing
complexes have been used widely, they suffer from leaching issues where non-metabolizable Gd3+
ions could potentially induce toxicity through accumulation in the body. Excessive Gd3+ toxicity could
lead to renal toxicity and inhibition of calcium channels in patients with insufficient renal function [7].
Therefore, discovering novel Gd-containing complexes with insignificant toxicity could be of potential
interest for researchers.
To date, gadolinium-based nanoparticles showed promising potential, and they have been
approved by the FDA for MRI imaging in cancer patients [8]. To improve Gd3+ leakage, carriers with a
higher degree of stability have been introduced [9]. In addition, liposome-based carriers containing
Gd have been found to have potential for improved tumor diagnosis [10].
In addition to the use of gadolinium for clinical diagnosis procedures, recently, complexes
containing contrast agents and drugs have been designed as potential platforms for drug delivery and
imaging applications. For instance, gadolinium-based cancer therapeutic liposomes have been utilized
to improve diagnosis and chemotherapy outcomes [11,12]. Dual functional liposomes were prepared
to encapsulate both doxorubicin and Gd via drug-metal complexation. The complex was found to be
potent in terms of a high accumulation of Gd nanoparticles in target tissues and a higher degree of
doxorubicin internalization. Similar studies were performed by fabricating Gd-doped layered double
hydroxide/Au nanocomposite. The synthesized nanoparticles showed high doxorubicin loading
capacity with a pH-responsiveness release profile. They were found to be able to release doxorubicin
in the cytoplasm [13]. In addition to the release profile, the loading of the molecular cargo into the
Gd-containing delivery system has been a challenging task. One of the most efficient methods is taking
advantage of π–π stacking interaction between the cargos and delivery systems [14]. This method can
be properly used for hydrophobic cargos containing benzene rings or similar scenarios for the delivery
systems. Generating a hydrophobic pocket using certain amino acids is one of the methods to entrap
the cargos. Additionally, a stimuli-responsive polymeric prodrug-based nanotheranostic system with
imaging agent (cyanine 5.5 and gadolinium-chelate) and a therapeutic agent paclitaxel (PTX) were
fabricated. The imaging-guided chemotherapy investigations to the 4T1 tumor in the mice model
showed an outstanding anti-tumor effect [15].
A peptide-based drug delivery system is one of the extensively used tools to overcome major
obstacles in permeation into cells. In recent years, synthetically engineered cyclic peptides have
been utilized as drug delivery systems for transporting various types of molecular cargos such as
anticancer drugs and siRNAs [16]. The cyclic nature of peptides has been discovered to be critically
important to enhance their intracellular transporting efficiency [17–19]. We introduced a class of
homochiral L-cyclic peptides with enhanced potency in nuclear targeting delivery of anti-HIV drugs
and biomolecules [20]. Unlike linear peptides, cyclic counterparts were found to be offering a preferred
orientation of guanidine groups and positive charge distribution on the surface of the peptide leading
to a higher level of cell permeability [20–22]. Additionally, the rigidity in the structure of peptides that
are obtained through cyclization makes them more stable in the presence of peptidases [23–26].
Although the synthesized cyclic peptides were found to be transporting drugs into cells efficiently,
their ability was improved exponentially when mixed with metal nanoparticles such as gold and
selenium [27–29]. The presence of arginine and tryptophan amino acids in their structures were highly
important to interact with positively charged metal ions and the cell membrane elements at the same
time. The presence of tryptophan and arginine amino acids in the structures of peptides induced
binding to metal nanoparticles through electrostatic and hydrophobic forces [30]. Therefore, various
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types of metals, in combination with peptides that can be used in drug delivery systems, have become
subjects of major interest.
In this work, we designed a drug delivery system containing both cyclic cell-penetrating peptide
and gadolinium (Gd) nanoparticles (CP-GdNPs). Gadolinium has already proved to be a convenient
choice for imaging due to its chemical and physical properties and high penetration. Here, we took
advantage of the unique nature of gadolinium and combined it with the bio-friendly nature of peptides
to introduce a new class of gadolinium-peptide-based drug delivery systems for carrying various types
of molecules. The ability of CP-GdNPs was evaluated for the delivery of a relatively large biomolecule
(a negatively charged phosphopeptide) in cell-based assays.
2. Materials and Methods
All amino acids and resins were purchased from AAPPTec, LLC (Louisville, KY, USA). All organic
solvents and reagents were purchased from Millipore Sigma Corporation (St. Louis, MO, USA) and
Fisher Scientific (Pittsburgh, PA, USA). Molecular weights of intermediate and final products were
confirmed by high-resolution matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF)
mass spectrometer from Bruker Inc. (GT 0264, Billerica, MA, USA). Intermediate and final compounds
were purified by reversed-phase high-performance liquid chromatography (RP-HPLC) from Shimadzu
(Prominence, Columbia, MD, USA) using a gradient system of acetonitrile and water with 0.1%
trifluoroacetic acid (TFA) using a reverse-phase column (XBridge BEH C18 OBD Prep Column), from
Waters Corporation (Milford, MA, USA).
2.1. Synthesis of Cyclic Peptide 1 [(WR)5 C]
The cyclic peptide containing eleven amino acids [CWRWRWRWRWR] was synthesized by
Fmoc/tBu solid-phase peptide synthesis. Arg(Pbf)-OH preloaded on 2-chlorotrityl resin (0.3 mmol,
524 mg, 0.572 mmol/g) was swollen in N,N-dimethylformamide (DMF) using agitation with purging
nitrogen. During the synthesis of the peptide, the Fmoc group was deprotected using 20% piperidine in
DMF (v/v) under nitrogen (20 min × 2). Coupling of each amino acid were performed using fmoc and
side chain-protected amino acids (0.9 mmol) using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU, 341 mg, 0.9 mmol, 3 equiv.) and diisopropylethylamine (DIPEA, 313
µL, 1.8 mmol) in DMF (15 mL) as coupling and activating reagents, respectively, for 90 min. After
every step (deprotection or coupling), the peptidyl resin was washed using DMF (20 mL × 3) and
excess solvent from resin were drained. The cycle of deprotection and coupling were followed
based on the sequence of peptide 1, e.g., in the order: Fmoc-Trp(Boc)-OH (474 mg, 0.9 mmol),
Fmoc-Arg(Pbf)-OH (584 mg, 0.9 mmol), Fmoc-Trp(Boc)-OH (474 mg, 0.9 mmol), Fmoc-Arg(Pbf)-OH
(584 mg, 0.9 mmol), Fmoc-Trp(Boc)-OH (474 mg, 0.9 mmol), Fmoc-Arg(Pbf)-OH (584 mg, 0.9 mmol),
Fmoc-Trp(Boc)-OH (474 mg, 0.9 mmol), Fmoc-Arg(Pbf)-OH (584 mg, 0.9 mmol), Fmoc-Trp(Boc)-OH
(474 mg, 0.9 mmol) and Fmoc-Cys(Trt)-OH (527 mg, 0.9 mmol). The N-terminal Fmoc group was
deprotected using 20% piperidine in DMF (20 min × 2). The peptidyl resin was used for cyclization
by agitation with freshly prepared cleavage cocktail, dichloromethane: 2,2,2-trifluoroethanol:acetic
acid (DCM:TFE:CH3 COOH; 7:2:1, v/v/v, 15 mL) for 1.5 h. The filtrate was collected and evaporated
completely and redissolved using 50 mL of DCM and evaporated. Cyclization was performed using
anhydrous DMF and DCM (50:50, v/v, 100 mL) using N,N’-diisopropylcarbodiimide (DIC, 71 µL,
0.45 mmol) and 1-hydroxy-7-azabenzotriazole (HOAt, 61 mg, 0.45 mmol) for 72 h to afford cyclic
peptide 1 after confirmation of mass of cyclized peptide with MALDI-TOF. The reaction mixture was
evaporated under reduced pressure and the cyclic peptide was fully deprotected after stirring with
freshly prepared cleavage cocktail, trifluoroacetic acid:triisopropylsilane:water (TFA:TIS:H2 O; 90: 5:5,
v/v/v, 13.5 mL: 750 µL: 750 µL) for 4 h. The crude cyclic peptide was precipitated by the addition of
cold diethyl ether (30 mL × 3) and purified by using RP-HPLC.
MALDI-TOF (m/z) for cyclic peptide 1 [(WR)5 C], C88 H116 N31 O11 S: calcd, 1814.9186; found
1814.7237 [M + H]+ .
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2.2. In Situ Preparation of Cyclic Peptide Gd Nanoparticles [(WR)5 C]-GdNPs
The formation reaction of gadolinium-peptide nanoparticles was carried out in aqueous media.
One milliliter of concentrated solution of peptide [(WR)5 C] (1 mM) was mixed with 1 mL aqueous
solution of GdCl3 (1 mM) at room temperature using a vortex mixer for 2 min. The mixing was
performed in a glass vial and monitored. The color or temperature of the solution did not change
upon mixing.
2.3. Transmission Electron Microscopy (TEM)
Samples for TEM imaging were prepared based on our previously reported method [18]. The
TEM [(WR)5 C]-GdNPs samples were prepared by placing a drop of original solution (5 µM) on an
ultrathin carbon type-A 400-mesh copper grid. They were allowed to dry in the presence of air. The
imaging process was conducted by EAG Laboratories (Sunnyvale, CA, USA) using FEI Techni TF-20
operated at 200 kV in brightfield TEM mode.
2.4. Zeta Potential Measurement
Zeta Potential technique was used to measure the surface charge of the nanoparticles before and
after loading with the cargo phosphopeptide (GpYEEI). Malvern Nano ZS Zetasizer (Westborough,
MA, USA) was used for the determination of zeta potential. The zeta potential of the complexes was
determined at 40 V using disposable folded capillary cells (DTS1070). The machine was calibrated
using zeta potential transfer standard DTS1235. Different concentrations of the phosphopeptide,
[(WR)5 C] and [(WR)5 C]-GdNPs were used for the determination of individual zeta potentials using
Smoluchowski approximation. All results were checked for the quality standard of the instrument.
2.5. Cell Culture
Two different cell lines, human leukemia T cells (CCRF-CEM, ATCC No. CCL-119) and breast
adenocarcinoma (MCF-7, ATCC No, HTB-22), were purchased from American Type Culture Collection
(ATCC) (Manassas, VA, USA). Cell culture supplies were purchased from Fisher Scientific (Pittsburgh,
PA, USA). Cells were proliferated on 75 cm2 cell culture flasks with RPMI-16 medium (for CCRF-CEM
cells) and EMEM medium (for MCF-7 cells), supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in 0.9% NaCl) in
a humidified atmosphere of 5% CO2 and 95% air at 37 ◦ C.
2.6. Cytotoxicity Assay of [(WR)5 C]-GdNPs
CCRF-CEM (50,000) cells were seeded in 96-well plates (0.1 mL/well) 24 h prior to the experiment.
The old medium (EMEM containing FBS (10%)) was changed (not in case of CCRF-CEM) by treatments
including [(WR)5 C], [(WR)5 C]-GdNPs and GdNPs (12.5–200 µM) in serum containing medium. The
cells were incubated for 24 h at 37 ◦ C in a humidified atmosphere of 5% CO2 . The viability of cells was
calculated using a SpectraMax M5 microplate spectrophotometer (Molecular Devices, San Jose, CA,
USA), with the absorbance intensity at 490 nm according to our previously reported method [20].
2.7. Time-Dependent Antiproliferative Activity Assay
Antiproliferative activities of several anticancer drugs, including epirubicin, cisplatin, gemcitabine,
etoposide, carboplatin and camptothecin, were evaluated in the presence and absence of
[(WR)5 C]-GdNPs in CCRF-CEM cells. Different time periods, including 24, 48 and 72 h, were
selected. The CellTiter 96 aqueous one solution cell proliferation assay kit (Promega, Madison, WI,
USA) was used for the assay. The CCRF-CEM cells (5 × 104 ) were seeded in 100 µL of the media.
The cells then placed in each well of the 96-well culture plate. The cells were incubated with drugs
alone and [(WR)5 C]-GdNPs-loaded drugs at a similar condition in triplicates. To confirm the results,
DMSO (1% in water) was used as a control. To entrap the drug, the physical mixing method was
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used. A calculated volume of the drug solution was mixed with the desired volume of an aqueous
solution of [(WR)5 C]-GdNPs physically to obtain a final concentration of the drug (5 µM) and the
[(WR)5 C]-GdNPs (50 µM). The mixture was vortexed until the solution became homogeneous and
clear. The mixture was incubated for 30 min at room temperature before adding to the cells to obtain
optimized performance. The incubation of cells with their treatments was carried out at 37 ◦ C for 24–72
h. The cell viability assay was performed by adding 20 µL of CellTiter 96 aqueous solution. The cells
were incubated for another hour with the MTS reagent. The formazan absorbance was measured at 490
nm by a microplate reader. The percentage of cell survival was calculated as previously reported [20].
2.8. Flow Cytometry Studies
Human leukemia cells (CCRF-CEM, 1 × 107 ) were plated in 6-well plates. Opti-MEM was
selected as a medium for cells and F0 -GpYEEI (5 µM) was added to all the wells. Then, a solution
of [(WR)5 C]–GdNPs (50 µM) in opti-MEM was added and cells were incubated for 2 h at 37 ◦ C. A
negative control containing F0 -GpYEEI (5 µM) alone was also incubated with cells in the same plate.
After 2 h, the cell treatments were removed, and cells were digested with 0.25% trypsin/EDTA (0.53
mM) for 5 min to detach any membrane-bound F0 -GpYEEI and artificial surface binding. After that,
PBS was used to wash the cells twice. The analysis of uptake was processed based on formerly reported
techniques and settings [20].
2.9. Confocal Microscopy on Live Cells
The MCF-7 cells were seeded in a glass bottom petri-dish (60 mm × 15 mm) of 5000 cells/mL of
opti-MEM for 24 h prior to the imaging. F0 -GpYEEI was mixed and incubated with [(WR)5 C]-GdNPs
(50 µM) for 30 min at room temperature. Then, the cells were treated with a mixture of F0 -GpYEEI (5
µM) and [(WR)5 C]-GdNPs (50 µM) for 2 h at 37 ◦ C. A solution of F0 -GpYEEI (5 µM) alone was used as
control. After 3 h, the medium containing the treatments was removed. The cells were washed with
PBS two times. Images were acquired by the Nikon A1R confocal microscope system that provides
high-resolution imaging of up to 4096 × 4096 pixels magnification for brightfield and FITC channels.
Images were merged and processed using Image J software (Fiji Version, NIH, Bethesda, MD, USA) to
visualize the fluorescence uptake by cells.
2.10. Cellular Release
The epirubicin intracellular release was investigated by using HPLC analysis. CCRF-CEM
cells were grown in 75 cm2 culture flasks with RPMI medium (containing 10% FBS and 1%
penicillin-streptomycin) to achieve ∼70–80% confluence (1 × 107 cells/mL). At the beginning, the
cells were seeded into 6-well plates (1 × 107 in 2 mL of medium per well). The epirubicin-loaded
[(WR)5 C]–GdNPs (5:50 µM, 1:10 ratio) was added to cells in medium. The cells were incubated for 2–72
h at 37 ◦ C. After the incubation time, the cells were collected and centrifuged. The supernatant was
removed. The cell pellets were washed by using ice-cold PBS (2 × 5 mL). The cell pellets were extracted
using a cocktail containing an equal volume of methanol, chloroform and isopropanol mixture (4:3:1,
v/v/v) and filtered through 0.2 µm filters. The solvents were evaporated under N2 gas. The sample
was dissolved in water and acetonitrile and run through HPLC system connected to UV/Vis detector
(490 nm) to measure the released epirubicin. The HPLC protocol was carried out was similar to our
previously reported method [29].
2.11. Statistical Analysis
To analyze the statistical significance of the dataset, different comparative studies such as cellular
uptake study, mechanism of cellular uptake and cell viability assay were performed. Cyclic peptide
[(WR)5 C] and [(WR)5 C]-GdNPs were compared in different treatment and different datasets were
collected. The datasets were used to test ANOVA single factor in MS Excel 2016 to find the p-values of
comparative datasets. p-value below 0.05 was considered as significant for all analyses. If a p-value
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An aqueous 10-mM solution of peptide [(WR)5 C] and GdCl3 was prepared and physically mixed
An aqueous 10-mM solution of peptide [(WR)5C] and GdCl3 was prepared and physically mixed
at room temperature. There was no change in color of solution after 8–10 h of incubation at room
at room temperature. There was no change in color of solution after 8–10 h of incubation at room
temperature. This resulted in the formation of Peptide–GdNPs. Cyclic peptide containing arginine
temperature. This resulted in the formation of Peptide–GdNPs. Cyclic peptide containing arginine
and tryptophan functioned as both reducing and capping agents for metal nanoparticles. Previously,
and tryptophan functioned as both reducing and capping agents for metal nanoparticles. Previously,
this combination has been able to generate gold and selenium nanoparticles successfully. This one-pot
this combination has been able to generate gold and selenium nanoparticles successfully. This onepot reaction does not require any additional surface modifying reagents. Mechanistically, tryptophan
was found to be a relatively strong reducing agent. Besides, the presence of positive charge in the
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The
Gd
nanoparticles
were
surrounded
and
covered
with
a layer peptide suggesting the presence
[32].
of non-covalent
covalent interaction
between and
gadolinium
and peptides
as a the
binding
The Gdornanoparticles
were surrounded
covered nanoparticles
with a layer peptide
suggesting
presence
non-covalent
or covalent
interaction amino
between
gadolinium
and
peptides as that
ligand.
It wasofpreviously
found
that tryptophan
acid
creates ananoparticles
hydrophobic
environment
binding
ligand.
It was
previously
found that
tryptophan
acid creates that
a hydrophobic
coulda serve
as an
effective
force
to form specific
structures.
It is amino
worth mentioning
the orientation
environment
that
could
serve
as
an
effective
force
to
form
specific
structures.
It
is
worth
mentioning
of amino acids in the structure of the peptide was found to be a significant element in the formation of
that the orientation of amino acids in the structure of the peptide was found to be a significant element
the morphology and size of these particles. However, more research is required to optimize the size
in the formation of the morphology and size of these particles. However, more research is required
and morphology of these nanoparticles.
to optimize the size and morphology of these nanoparticles.

Figure 2. TEM images of [(WR)5C]–GdNPs.
Figure
2. TEM images of [(WR)5 C]–GdNPs.

3.4. Zeta
Potential
Measurement
3.4. Zeta
Potential
Measurement
To evaluate the binding affinity between peptide-capped nanoparticles and negatively charged
To evaluate
the binding affinity between peptide-capped nanoparticles and negatively charged
phosphopeptides, the surface charge of [(WR)5C]-GdNPs was measured before and after loading
phosphopeptides, the surface charge of [(WR)5 C]-GdNPs was measured before and after loading
with the phosphopeptide, GpYEEI. The ratio and concentration were selected to be similar to that of
with biological
the phosphopeptide,
GpYEEI. The ratio and concentration were selected to be similar to that of
assays. Thus, the surface charge of [(WR)5C]-GdNPs (50 µM) alone, GpYEEI (5 µM) alone
biological
assays.
Thus,
the
surface
charge
of [(WR)
µM) alone,
GpYEEI
(5results
µM) alone
5 C]-GdNPs
and [(WR)5C]-GdNPs loaded
GpYEEI
mixture
(50 µM:5
µM) were(50
obtained.
The zeta
potential
and [(WR)
C]-GdNPs
loaded
GpYEEI
mixture
(50 alone,
µM:5 GpYEEI
µM) were
obtained.
The5C]-GdNPs
zeta potential
results
show 5that
the surface
charge
of [(WR)
5C]-GdNPs
alone,
and [(WR)
loaded
showGpYEEI
that themixture
surfacewere
charge
of [(WR)
C]-GdNPs
alone,
GpYEEI
alone,
and
[(WR)
C]-GdNPs
loaded
found
to be 24,
−2
and
21
mV.
These
data
show
that
the
positive
charge
of
5
5
peptide-gadolinium
nanoparticles
reduced
theThese
presence
of the
GpYEEI
mixture were found
to be 24, −2
and 21inmV.
data show
that negatively-charged
the positive charge of
phosphopeptide,nanoparticles
suggesting electrostatic
is oneof
ofthe
the negatively-charged
contributing forces inphosphopeptide,
the binding
peptide-gadolinium
reduced interaction
in the presence
process. All results meet the quality criteria of the Zetasizer instrument.
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Encapsulation of
of Camptothecin
3.5. Encapsulation
Camptothecin by
by Peptide-GdNPs
Peptide-GdNPs
To
To validate
validate [(WR)
[(WR)55C]-GdNPs
C]-GdNPs for
for entrapping
entrapping clinically
clinically available
available drugs,
drugs, camptothecin
camptothecin (CPT)
(CPT) was
was
chosen
as
a
model
drug
in
fluorescence
spectroscopy
investigations.
CPT
is
known
as
a
topoisomerase
chosen as a model drug in fluorescence spectroscopy investigations. CPT is known as a
Itopoisomerase
Inhibitor withI aInhibitor
hydrophobic
structure
[33]. structure
The spectroscopy
results show results
a significant
with achemical
hydrophobic
chemical
[33]. The spectroscopy
show
blue
shift
in
maxima’s
emission
of
CPT
fluorescence
spectra.
Due
to
the
interaction
of
CPT with
a significant blue shift in maxima’s emission of CPT fluorescence spectra. Due to the interaction
of
[(WR)
C]-GdNPs,
the
characteristic
CPT’s
maxima
peak
at
432
nm
was
shifted
to
417
nm
(Figure
3).
The
5
CPT with [(WR)5C]-GdNPs, the characteristic CPT’s maxima peak at 432 nm was shifted to 417 nm
involved
hydrophobic
forces
between CPT
andbetween
[(WR)5 C]-GdNPs
be responsible for the
(Figure 3).
The involved
hydrophobic
forces
CPT and could
[(WR)possibly
5C]-GdNPs could possibly be
observed
blue
shift
of
CPT’s
peak
in
the
presence
of
[(WR)
C]-GdNPs.
In
addition,
the peak
intensity
responsible for the observed blue shift of CPT’s peak in the5 presence of [(WR)5C]-GdNPs.
In addition,
of
was
reduced
due tosignificantly
the self-quenching
drug and
the outcome
of
theCPT
peak
intensity
ofsignificantly
CPT was reduced
due to of
thebounded
self-quenching
of also
bounded
drug and
the
partitioning
and
entrapment
in
the
hydrophobic
pocket
generated
by
the
[(WR)
C]-GdNPs
[19].
5
also the outcome of the partitioning and entrapment in the hydrophobic pocket generated by the
The
encapsulation
findings show that the [(WR)5 C]-GdNPs
were
of entrapping
CPT
because
[(WR)
5C]-GdNPs [19]. The encapsulation findings
show that
thecapable
[(WR)5C]-GdNPs
were
capable
of
of
the
hydrophobic
pockets
possibly
generated
by
involved
tryptophans.
entrapping CPT because of the hydrophobic pockets possibly generated by involved tryptophans.

Figure 3. Fluorescence spectra of CPT in the presence of [(WR)5 C]-GdNPs (1:1 molar ratio) after
Figure 3. Fluorescence spectra of CPT in the presence of [(WR)5C]-GdNPs (1:1 molar ratio) after 2-h
2-h incubation.
incubation.

3.6. Cytotoxicity of Peptide-GdNPs
3.6. Cytotoxicity of Peptide-GdNPs
The cytotoxicity of freshly synthesized [(WR)5 C]-GdNPs was tested in human leukemia
The cytotoxicity
ofconcentrations
freshly synthesized
[(WR)
5C]-GdNPs
testedselected.
in human
leukemia
(CCRF(CCRF-CEM)
cells. The
12.5, 25,
50, 100,
and 200 was
µM were
The
peptide-capped
CEM) cells. nanoparticles
The concentrations
12.5,
25,significant
50, 100, and
200 µM
were
gadolinium
did not
show
toxicity
(~93%
cellselected.
viability The
at 50peptide-capped
µM) after 24 h
gadolinium
did not show
significant
toxicityinvestigations,
(~93% cell viability
at 50 µM) after
of
of
incubationnanoparticles
(Figure 4). Therefore,
for further
cell-based
the concentration
of 24
50 h
µM
incubation
(Figure
4).
Therefore,
for
further
cell-based
investigations,
the
concentration
of
50
µM
was
was chosen.
chosen.
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Figure 4. Cytotoxicity of [(WR)5C] and [(WR)5C]-GdNPs after 24-h incubation. (if p < 0.05 then *, if p
Figure 4.
4. Cytotoxicity
Cytotoxicity of
<
Figure
of [(WR)
[(WR)55C]
C] and
and [(WR)
[(WR)55C]-GdNPs
C]-GdNPs after
after24-h
24-hincubation.
incubation.(if
(ifpp<<0.05
0.05then
then*,*,ififp p
< 0.01 then **, if p < 0.0001 then ****).
0.01
then
**,
if
p
<
0.0001
then
****).
< 0.01 then **, if p < 0.0001 then ****).

3.7.
3.7.Evaluation
EvaluationofofPeptide-GdNPs
Peptide-GdNPsasasMolecular
MolecularTransporters
Transporters
3.7. Evaluation of Peptide-GdNPs as Molecular Transporters
To
To obtain
obtain aa sufficient
sufficient understanding
understanding of
of the
the potential
potential of
of [(WR)
[(WR)5C]-GdNPs
C]-GdNPsfor
for carrying
carryingcargos
cargos
To obtain a sufficient understanding of the potential of [(WR)55C]-GdNPs for carrying cargos
intracellularly,
intracellularly, the
the flow
flow cytometry
cytometry method
method was used. AA fluorescence-labeled
fluorescence-labeled cell
cell impermeable
impermeable
intracellularly, the flow cytometry method
was used. A fluorescence-labeled cell impermeable
negatively
negativelycharged
chargedphosphopeptide,
phosphopeptide,F′-GpYEEI,
F0 -GpYEEI,was
wasselected
selectedas
asaacargo
cargomodel.
model.GpYEEI
GpYEEImimics
mimicsthe
the
negatively charged phosphopeptide, F′-GpYEEI, was selected as a cargo model. GpYEEI mimics the
pTyr1246
ErbB2
SH2[34].
domain
[34]. Traditionally,
delivery of
pTyr1246 ofofErbB2
thatthat
bindsbinds
to the to
Chkthe
SH2Chk
domain
Traditionally,
the delivery of the
phosphopeptides
pTyr1246 of ErbB2 that binds to the Chk SH2 domain [34]. Traditionally, the delivery of
phosphopeptides
is a due
challenging
task dueoftonegatively
the presence
of negatively
charged
phosphate
groups.
is a challenging task
to the presence
charged
phosphate
groups.
At the same
time,
phosphopeptides is a challenging task due to the presence of negatively charged phosphate groups.
At
thesize
same
time, their
sizeto
is enter
another
barrier
to entercells
cells.
CCRF-CEM
cells
were
selected
this
their
is another
barrier
cells.
CCRF-CEM
were
selected for
this
assay.
FACS for
analysis
At the same time, their size is another
barrier to enter cells. CCRF-CEM cells were selected for this
assay.
FACS
analysis
revealed
thatof
theF0cellular
uptake
of was
F′-GpYEEI
(5 µM)
wasfolds
enhanced
six folds
revealed
that
the cellular
uptake
-GpYEEI
(5 µM)
enhanced
by six
in the by
presence
of
assay. FACS analysis revealed that the cellular uptake of F′-GpYEEI (5 µM) was enhanced by six folds
in
the
presence
of
[(WR)
5
C]-GdNPs
(50
µM)
compared
to
that
of
phosphopeptide
alone
(Figure
5).
[(WR) C]-GdNPs (50 µM) compared to that of phosphopeptide alone (Figure 5). These data suggest
in the 5presence of [(WR)5C]-GdNPs (50 µM) compared to that of phosphopeptide
alone (Figure 5).
These
data 5suggest
thatmay
[(WR)
5C]-GdNPs
may potentially
function
as a delivery
toolintracellularly.
to carry F′that [(WR)
C]-GdNPs
potentially
function
as a delivery
tool to carry
F0 -GpYEEI
These data suggest that0 [(WR)5C]-GdNPs may potentially function as a delivery tool to carry F′GpYEEI
intracellularly.
The cellular
of F′-GpYEEI
was notof improved
thesolution
presence
of
The cellular
uptake of F -GpYEEI
was uptake
not improved
in the presence
gadoliniuminsalt
alone,
GpYEEI intracellularly. The cellular uptake of F′-GpYEEI was not improved in the presence of
gadolinium
salt solution
alone,
the presence
of complex
peptides isincritical
the structure
of the
suggesting that
the presence
of suggesting
peptides inthat
the structure
of the
for improving
gadolinium salt solution alone, suggesting that the presence of peptides in the structure of the
complex
is critical for improving the uptake.
the uptake.
complex is critical for improving the uptake.

Figure5.5. Cellular
Cellularuptake
uptakeof
ofF′-GpYEEI
F0 -GpYEEIininthe
thepresence
presenceof
of [(WR)
[(WR)55C]
C]and
and[(WR)
[(WR)5C]-GdNPs
(50µM)
µM)
5 C]-GdNPs(50
Figure
Figure
5.
Cellular
uptake
of
F′-GpYEEI
in
the
presence
of if
[(WR)
5C] and [(WR)5C]-GdNPs (50 µM)
after
2-h
incubation
in
CCRF-CEM
cells.
(if
p
<
0.01
then
**,
p
<
0.0001
then
****).
after 2-h incubation in CCRF-CEM cells. (if p < 0.01 then **, if p < 0.0001 then ****).
after 2-h incubation in CCRF-CEM cells. (if p < 0.01 then **, if p < 0.0001 then ****).
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The
intracellular
F0 -GpYEEI (5 µM) was also improved by peptide alone 10
compared
0
to that of F -GpYEEI alone. However, the presence of gadolinium enhanced the uptake even
The intracellular uptake of F′-GpYEEI (5 µM) was also improved by peptide alone compared to
further by approximately 1.7 folds in comparison with that of peptide alone. Another control
that of F′-GpYEEI alone. However, the presence of gadolinium 0enhanced the uptake even further by
experiment
was performed by using the phosphopeptide (F -GpYEEI) alone. These results show
approximately 1.7 folds in comparison with that of peptide alone. Another control experiment was
that, although
of the peptide is(F′-GpYEEI)
necessary for
enhanced
delivery
efficiency
of thethe
carrier,
performedthe
by presence
using the phosphopeptide
alone.
These results
show
that, although
the gadolinium
nanoparticles
improveforthe
cellulardelivery
uptakeefficiency
of the drug,
the uptake
presence of the
peptide is necessary
enhanced
of thesuggesting
carrier, the that
gadolinium
of thenanoparticles
drug was significantly
presumably
due
to the new
of the
amino
improve the enhanced,
cellular uptake
of the drug,
suggesting
thatorientation
the uptake of
drugacids
was and
significantly
enhanced,
presumably
due
to
the
new
orientation
of
amino
acids
and
gadolinium
gadolinium nanoparticles.
nanoparticles.
Confocal
microscopy was used to visualize the comparative enhancement of intracellular uptake
Confocal
microscopy
was
usedThe
to visualize
thewere
comparative
intracellular
0
of F -GpYEEI
(5 µM)
in MCF-7
cells.
cells that
treatedenhancement
with only F0of
-GpYEEI
did uptake
not exhibit
of F′-GpYEEI (5 µM) in MCF-7 cells. The cells that were treated with only F′-GpYEEI did not exhibit
any detectable fluorescence intensity during imaging. The microscopy imaging exhibited higher
any detectable fluorescence intensity during imaging. The microscopy imaging exhibited higher
fluorescence intensity in the presence of F0 -GpYEEI [(WR)5 C]-GdNPs (50 µM) compared to that of
fluorescence intensity
in the presence of F′-GpYEEI [(WR)5C]-GdNPs (50 µM) compared to that of
phosphopeptide
(F0 -GpYEEI)
alone
(Figure
phosphopeptide
(F′-GpYEEI)
alone
(Figure6).
6).

0 -GpYEEIuptake
Figure
6. Confocal
microscopeimages
images of
of FF′-GpYEEI
cells
in the
presence
of of
Figure
6. Confocal
microscope
uptakebybyMCF-7
MCF-7
cells
in the
presence
[(WR)
5C]-GdNPs after 2-h incubation.
[(WR)5 C]-GdNPs after 2-h incubation.

3.8. Mechanistic
Studies
of Cellular
Internalization
3.8. Mechanistic
Studies
of Cellular
Internalization
The mechanism
of cellular
internalization has
has always
area
of interest
for researchers.
The mechanism
of cellular
internalization
alwaysbeen
beenanan
area
of interest
for researchers.
When cargos approach the cell membrane, they can enter cells through various mechanisms,
When cargos approach the cell membrane, they can enter cells through various mechanisms,
including phagocytosis, micropinocytosis and receptor-mediated endocytosis. Receptor-mediated
including phagocytosis, micropinocytosis and receptor-mediated endocytosis. Receptor-mediated
endocytosis (RME) route could include various pathways such as clathrin-mediated, caveolaeendocytosis
(RME)
route could include various pathways
such
as clathrin-mediated,
caveolae-mediated
mediated
and caveolae/clathrin-independent
endocytosis
[33–35].
To find the mechanism
of uptake
and caveolae/clathrin-independent
endocytosis
[33–35]. quantitative
To find theFACS
mechanism
of uptake
of cargo-loaded-peptide-capped gadolinium
nanoparticles,
studies were
used. of
cargo-loaded-peptide-capped
nanoparticles,
quantitative
FACS
were used. The
The fluorescence intensity ofgadolinium
F′-GpYEEI loaded
[(WR)5C]-GdNPs
(5:50 µM)
was studies
tested quantitatively
in the presence
of several
endocytic loaded
inhibitors,
namely
chloroquine,
nystatin,
chlorpromazine,
5-(Nfluorescence
intensity
of F0 -GpYEEI
[(WR)
(5:50
µM) was
tested quantitatively
5 C]-GdNPs
ethyl-N-isopropyl)-amiloride
(EIA)
and
methyl-β-cyclodextrin,
by
using
FACS
(Figure
7).
in the presence of several endocytic inhibitors, namely chloroquine, nystatin, chlorpromazine,
5-(N-ethyl-N-isopropyl)-amiloride (EIA) and methyl-β-cyclodextrin, by using FACS (Figure 7).
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Figure
7. Cellular
uptake
of of
F0F′-GpYEEI
-GpYEEI loaded
[(WR)55C]-GdNPs
C]-GdNPs
absence
or presence
of different
Figure
7. Cellular
uptake
loaded [(WR)
in in
thethe
absence
or presence
of different
endocytic
inhibitors
in MCF-7
cellsafter
after22h.
h. (if
(if p <
< 0.001
if p
thenthen
****).****).
endocytic
inhibitors
in MCF-7
cells
0.001then
then***,
***,
if <p 0.0001
< 0.0001

As showed
Figure 7, no
decrease
of theof
fluorescence
signal of F′-GpYEEI
As showed
ininFigure
nosignificant
significant
decrease
the fluorescence
signal of loaded
F0 -GpYEEI
[(WR)
5C]-GdNPs was observed in MCF-7 cells when chloroquine, chlorpromazine and methyl-βloaded
[(WR)
5 C]-GdNPs was observed in MCF-7 cells when chloroquine, chlorpromazine and
cyclodextrin
were present
after 2 h after
of incubation
at 37 °C. These
reveal
that the
clathrin◦ C. These
methyl-β-cyclodextrin
were present
2 h of incubation
at 37findings
findings
reveal
that the
mediated or caveolae-mediated endocytosis and phagocytosis are not majorly responsible pathways
clathrin-mediated or caveolae-mediated endocytosis and phagocytosis are not majorly responsible
for the uptake. Macropinocytosis was found to be an important pathway because the uptake of the
pathways for the uptake. Macropinocytosis was found to be an important pathway because the uptake
complex was reduced in the presence of nystatin and EIA by 40% and 45%, respectively. The FACS
of theresults
complex
was 7reduced
in the
presence
nystatin
andreduced
EIA bythe
40%
and 45%, respectively.
in Figure
reveal that,
although
theseoftwo
inhibitors
internalization
of the cargo The
FACSsignificantly,
results in Figure
7 reveal
that,down
although
these two
inhibitors
reduced other
the internalization
they could
not shut
the pathway
completely,
suggesting
pathways couldof the
cargoalso
significantly,
they could
not transporting
shut down the
pathway completely,
suggesting
other
pathways could
be involved
here in
F′-GpYEEI
loaded [(WR)
5C]-GdNPs
intracellularly.
0 -GpYEEI loaded
Additionally,
the cellular
uptake ofFF′-GpYEEI
was
reduced
by
50%
when
also be
involved here
in transporting
loaded[(WR)
[(WR)5C]-GdNPs
C]-GdNPs
intracellularly.
Additionally,
5
0
cells
were
incubated
at
4
°C.
These
results
potentially
suggest
that
the
mechanism
of
uptake
is a were
the cellular uptake of F -GpYEEI loaded [(WR)5 C]-GdNPs was reduced by 50% when cells
◦
partially
energy-dependent
pathway.
incubated at 4 C. These results potentially suggest that the mechanism of uptake is a partially
Gadolinium
nanoparticles have already been used for MRI imaging; thus, they are promising
energy-dependent
pathway.
platforms for delivery applications. However, the functionalization of the surface of gadolinium
Gadolinium nanoparticles have already been used for MRI imaging; thus, they are promising
nanoparticles with [(WR)5C] peptide make them more intractable with the cell membrane. The nature
platforms for delivery applications. However, the functionalization of the surface of gadolinium
of this interaction consists of electrostatic interactions and hydrophobic forces generated by arginine
nanoparticles
with [(WR)
C] peptide
make them
more intractable
the cellof
membrane.
nature
and tryptophan
amino5acids,
respectively.
The functional
groups in with
the structure
these aminoThe
acids
of this
interaction
consists
of
electrostatic
interactions
and
hydrophobic
forces
generated
by
arginine
could induce binding affinity with the negatively charged phospholipids in the cell membrane. This
and tryptophan
aminoby
acids,
respectively.
functional
groups
in the
structure
of these amino
interaction follows
hydrophobic
forcesThe
induced
via indole
groups
available
in tryptophan
amino acids
leading
to higher
intracellular
penetration
due
to disturbed
lipid bilayer
thecell
structure
of the This
couldacid
induce
binding
affinity
with the
negatively
charged
phospholipids
ininthe
membrane.
cell membrane.
last step of thisforces
process
is peptide
into
the membrane
to enhance
interaction
follows The
by hydrophobic
induced
viainternalization
indole groups
available
in tryptophan
amino
the cellular
uptake intracellular
of the cargo. The
mechanism
cellular
internalization
of the
peptide
was found
acid leading
to higher
penetration
dueofto
disturbed
lipid bilayer
in the
structure
of the cell
to be partially
energy
independent.
When
the peptide
was mixed with
GdNPs,
the mechanism
of the
membrane.
The last
step of
this process
is peptide
internalization
into the
membrane
to enhance
uptake favors the energy-dependent mechanism, suggesting gadolinium nanoparticles are
cellular uptake of the cargo. The mechanism of cellular internalization of the peptide was found to be
partially energy independent. When the peptide was mixed with GdNPs, the mechanism of uptake
favors the energy-dependent mechanism, suggesting gadolinium nanoparticles are responsible for
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responsible
for the uptake. Thus, the gadolinium nanoparticles influence the mechanism of uptake.
However, more investigations are needed to find the detailed mechanism of cell entry of [(WR)5C]GdNPs.
the uptake. Thus, the gadolinium nanoparticles influence the mechanism of uptake. However, more

investigations are needed to find the detailed mechanism of cell entry of [(WR)5 C]-GdNPs.
3.9. Intracellular Release of Epirubicin
3.9. Intracellular
Release
of Epirubicin drug release in a timely manner, epirubicin was selected to be a
To investigate
the intracellular

model
Analytical
HPLC technique
used
study manner,
the release
of epirubicin
intracellularly
Todrug.
investigate
the intracellular
drug was
release
in to
a timely
epirubicin
was selected
to be a
7) were treated
by
[(WR)
5C]-GdNPs-epirubicin
complex in
CCRF-CEM
cells.the
CCRF-CEM
cells (1.2 × 10
model
drug.
Analytical HPLC technique
was
used to study
release of epirubicin
intracellularly
by
7
by
epirubicin
(5
µM)-loaded
[(WR)
5
C]-GdNPs
(50
µM)
for
different
incubation
times
(12–48
h).
The
[(WR)5 C]-GdNPs-epirubicin complex in CCRF-CEM cells. CCRF-CEM cells (1.2 × 10 ) were treated by
amount
of (5
epirubicin
was[(WR)
measured
using (50
HPLC
490
nm. HPLC
data show
[(WR)
C]-GdNPsepirubicin
µM)-loaded
µM)atfor
different
incubation
timesthat
(12–48
h). 5The
amount
5 C]-GdNPs
epirubicin
releases
epirubicin
in
a
time-dependent
manner:
approximately
15%
and
60%
of
epirubicin
of epirubicin was measured using HPLC at 490 nm. HPLC data show that [(WR)5 C]-GdNPs-epirubicin
was
released
intracellularly
within 12 and
48 h, respectively.
These
suggest
the sustained
release
releases
epirubicin
in a time-dependent
manner:
approximately
15% data
and 60%
of epirubicin
was released
of
epirubicin contributes
to 48
the
activity
of data
the epirubicin-loaded
[(WR)
5C]-GdNPs
as a
intracellularly
within 12 and
h, overall
respectively.
These
suggest the sustained
release
of epirubicin
potential
prodrug.
contributes to the overall activity of the epirubicin-loaded [(WR)5 C]-GdNPs as a potential prodrug.
3.10. Time-Dependent
Time-Dependent Antiproliferative
Antiproliferative Activity
Activity Assay
3.10.
Several anticancer
anticancer drugs
drugs such
such as
as epirubicin,
epirubicin, cisplatin,
cisplatin, gemcitabine,
gemcitabine, etoposide,
etoposide, carboplatin
carboplatin and
and
Several
camptothecin were
were evaluated
evaluated for
for their
their antiproliferative
antiproliferative activities
activities at
at different
different time
time periods,
periods, including
including
camptothecin
24, 48
48 and
and 72
72 h.
h. The
Theresults
resultsof
ofantiproliferative
antiproliferativeassay
assayexhibit
exhibitthat
thatthe
thepotency
potencyof
ofepirubicin,
epirubicin,cisplatin,
cisplatin,
24,
gemcitabine,
etoposide,
carboplatin
and
camptothecin
(5
µM)
was
enhanced
by
6%,
41%,
10%,
2%,
gemcitabine, etoposide, carboplatin and camptothecin (5 µM) was enhanced by 6%, 41%, 10%, 2%,
18% and
and 8%,
8%, respectively,
respectively, in the presence of [(WR)55C]-GdNPs
C]-GdNPs (50
(50 µM)
µM) in
in CCRF-CEM
CCRF-CEM cells
cells after
after 72
72 hh
18%
of incubation
incubation(Figure
(Figure8).
8).The
Theimproved
improved
antiproliferative
activity
cisplatin
and
carboplatin
could
of
antiproliferative
activity
of of
cisplatin
and
carboplatin
could
be
be due
to chelating
the chelating
ofthiol
the thiol
of cysteine
with anticancer
these anticancer
or binding
of
due
to the
of the
groupgroup
of cysteine
with these
agents agents
or binding
of metals
metals
to peptides
as GdNPs.
As evident
in8,Figure
8, the antiproliferative
these anticancer
to
peptides
as GdNPs.
As evident
in Figure
the antiproliferative
activity activity
of theseof
anticancer
drugsdrugs-loaded
was generally
time-dependent
in most
could
happen
loaded
[(WR)5[(WR)
C]-GdNPs
was generally
time-dependent
in most
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4. Conclusions
A new metal-containing drug delivery system was designed using gadolinium nanoparticles and
cyclic peptides containing tryptophan, cysteine and arginine amino acids. [(WR)5 C]-GdNPs exhibited
notable interaction with CPT through non-covalent interactions. The complex functioned as a carrier
to deliver a negatively charged cell-impermeable phosphopeptide (F0 -GpYEEI) into cells. The uptake
efficiency of the molecular cargo in the presence of the carrier complex was confirmed by confocal
microscopy. Time-dependent antiproliferative studies showed that multiple anticancer drugs such as
epirubicin, cisplatin, gemcitabine, etoposide, carboplatin and camptothecin can inhibit the proliferation
of CCRF-CEM cells after 72 h of incubation by 6%, 41%, 10%, 2%, 18% and 8%, respectively, when
combined with [(WR)5 C]-GdNPs (50 µM). This investigation provides further understanding of how
to take advantage of gadolinium for the efficient delivery of cell-impermeable cargo molecules in
combination with peptides. The peptide reduces the toxicity of the metal, while also enhancing the
intracellular uptake.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/9/792/s1, the
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